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Abstract
 
A number of diseases are due to lysosomal destabilization, which results in damaging cell loss.
To investigate the mechanisms of lysosomal cell death, we characterized the cytotoxic action of
two widely used quinolone antibiotics: ciprofloxacin (CPX) or norfloxacin (NFX). CPX or
NFX plus UV light (NFX
 
*
 
) induce lysosomal membrane permeabilization (LMP), as detected
by the release of cathepsins from lysosomes. Inhibition of the lysosomal accumulation of CPX
or NFX suppresses their capacity to induce LMP and to kill cells. CPX- or NFX-triggered
LMP results in caspase-independent cell death, with hallmarks of apoptosis such as chromatin
condensation and phosphatidylserine exposure on the plasma membrane. LMP triggers mito-
chondrial membrane permeabilization (MMP), as detected by the release of cytochrome 
 
c
 
.
Both CPX and NFX
 
*
 
 cause Bax and Bak to adopt their apoptotic conformation and to insert
into mitochondrial membranes. Bax
 
 
 
/
 
 
 
 Bak
 
 
 
/
 
 
 
 double knockout cells fail to undergo MMP
and cell death in response to CPX- or NFX-induced LMP. The single knockout of Bax or Bak
(but not Bid) or the transfection-enforced expression of mitochondrion-targeted (but not endo-
plasmic reticulum–targeted) Bcl-2 conferred protection against CPX (but not NFX
 
*
 
)-induced
MMP and death. Altogether, our data indicate that mitochondria are indispensable for cell
death initiated by lysosomal destabilization.
Key words: Bax • Bcl-2 • apoptosis • autophagy • caspases
 
Introduction
 
The ultimate morphological and biochemical features of
apoptotic cells are largely independent of the death-initiat-
ing pathway, a fact that led to the concept of the “central
executioner,” a self-amplifying device that involves caspase
activation cascades and/or mitochondrial membrane per-
meabilization (MMP;
 
*
 
 references 1, 2). Caspase activation
and MMP are intimately linked because MMP stimulates
caspase activation through the mitochondrial release of sev-
eral caspase-activating proteins, in particular cytochrome 
 
c
 
(3). Conversely, caspase activation culminates in the pro-
teolytic maturation of proteins (e.g., truncated Bid, Bad,
Bcl-X
 
L
 
, etc.), which trigger MMP (2, 4). MMP manifests
at the level of the outer membrane, which allows for the
release of cytochrome 
 
c
 
, as well as at the level of the inner
membrane as a loss of the mitochondrial transmembrane
potential (
 
  
 
m
 
; references 1, 2). MMP-mediated control
of cell death has been firmly established by the fact that
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Abbreviations used in this paper:
 
 AO, acridine orange; Baf A
 
1
 
, Bafilomy-
cin A
 
1
 
; CPX, ciprofloxacin; 
 
  
 
m
 
, mitochondrial transmembrane poten-
tial; DAPI, 4
 
 
 
,6-diamidino-2-phenylindole; DiOC
 
6
 
(3), 3,3
 
 
 
 dihexyloxa-
carbocyanine iodide; DKO, double knockout; GFP, green fluorescent
protein; JC-1, 5,5
 
 
 
,6,6
 
 
 
-tetrachloro-1,1
 
 
 
,3,3
 
 
 
-tetraethylbenzimidazolyl-
carbocyanine iodide; LMP, lysosomal membrane permeabilization; MEF,
mouse embryonic fibroblasts; MMP, mitochondrial membrane permeabi-
 
lization; NFX, norfloxacin; NFX
 
*
 
, NFX plus UV light; PI, propidium
iodide; PS, phosphatidylserine; ROS, reactive oxygen species; z-FA-fmk,
 
N
 
-benzyloxycarbonyl-Phe-Ala-fluoromethylketone; z-VAD-fmk, 
 
N
 
-benz-
yloxycarbonyl-Val-Ala-Asp-fluoromethylketone.T
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mouse embryonic fibroblasts (MEF) lacking both Bax and
Bak, two proteins required for MMP induction, are pro-
tected against a plethora of different apoptotic stimuli (5).
Moreover, Bcl-2 and Bcl-X
 
L
 
, two proteins inserted into
the outer mitochondrial membrane as well as other intra-
cellular membranes, inhibit apoptosis, at least in part, by
preventing MMP (1, 2, 6). Thus far, it has been established
that MMP is a rate-limiting step for cell death induction
when apoptosis is triggered, in an organelle-specific fash-
ion, by the nuclear DNA damage response, by the un-
folded stress response at the level of the endoplasmic reticu-
lum (ER), or by mitochondrial dysfunction (4).
Lysosomes, which have been referred to as “suicide
bags,” notoriously contribute to autophagic cell death (also
called “type II” cell death; references 7–9). Recent obser-
vations suggest that p53 can trigger a primary lysosomal de-
stabilization that contributes to cell death via apoptosis (10).
In pro-oxidant–induced apoptosis, the release of cathepsin
D from lysosomes reportedly precedes the release of cyto-
chrome 
 
c
 
 from mitochondria (11). Ceramide generated by
the lysosomal sphingomyelinase can trigger the proteolytic
autoactivation of cathepsin D (12). Hepatocytes from ca-
thepsin B knockout mice are relatively resistant to
TNF-
 
 
 
–induced apoptosis (13), and cathepsin B partici-
pates in TNF-
 
 
 
-induced, caspase-independent cell death of
WEHI-S cells (14). Enzymatic defects resulting in lysoso-
mal destabilization can cause unwarranted (possibly apop-
totic) cell loss, in particular in the central nervous system.
This applies to clinically important diseases such as Sand-
hoff disease, Gaucher disease, Farber’s disease, Niemann
Picks’ disease, and neural ceroid lipofuscinosis (4).
In spite of this wealth of information, it is currently un-
known to what extent MMP is required for cell death initi-
ated at the lysosomal level. On theoretical grounds, two
possibilities could be envisioned. On the one hand, MMP
could be a rate-limiting step of lysosome-initiated death,
which would be in line with the idea that MMP would be
part of the “central executer” (1) or “gateway to death”
(5). On the other hand, some data suggest that lysosomal
destabilization and cathepsins might trigger cell death via
novel, MMP-independent pathways, e.g., via direct cathep-
sin effects on the nucleus (9, 15, 16).
Lysosomotropic agents are lipophilic bases that accumu-
late in the lysosomal lumen and can exert detergent-like or
local phototoxic effects on lysosomal membranes. Two
quinolone antibiotics, norfloxacin (NFX) and ciprofloxacin
(CFX), which are used on millions of patients each year,
are lysosomotropic and can induce apoptosis either in the
presence (NFX) or absence (CFX) of a low dose of UV
light (17–19). This property may explain the unwarranted
cytotoxicity of such compounds (and, in particular, the del-
eterious effect of NFX medication plus sunlight exposure)
and lead to the proposal that quinolone antibiotics could be
used for cancer therapy (19).
Here, we show that NFX and CFX kill cells through a
lysosomal mechanism. Using NFX and CFX as specific
tools for the organelle-specific initiation of cell death, we
addressed the functional hierarchy between lysosomes,
MMP, and caspases. Our results indicate that MMP medi-
ated by Bax and/or Bak is strictly required for the induc-
tion of cell death through a caspase-independent pathway
initially triggered at the lysosomal level.
 
Materials and Methods
 
Cell Lines, Culture Conditions, and Transfection. 
 
HeLa cells
were stably transfected with pcDNA3.1 control vector (Neo),
with human Bcl-2 (Bcl-2) or the cytomegalovirus UL37 exon 1
gene (vMIA, provided by Dr. V. Goldmacher, ImmunoGen,
Cambridge, MA; reference 20), or a histone H2B–green fluores-
cent protein (GFP) fusion construct (H2B-GFP, a gift from Dr.
G.M. Wahl, Salk Institute, La Jolla, CA; reference 21). Rat-1/
myc fibroblasts (provided by Dr. D. Andrews, McMaster Univer-
sity, Hamilton, Canada) were stably transfected with pRc/CMV-
based plasmids (Neo) and constitutively express human Bcl-2,
mitochondrion-targeted Bcl-2 acta, and ER-targeted Bcl2-cb5
(22, 23). Cells were cultured in DMEM supplemented with 10%
FCS, 1 mM of pyruvate, 10 mM Hepes, and 100 U/ml penicil-
lin/streptomycin at 37
 
 
 
C under 5% CO
 
2
 
. SV40-transformed
MEF, whose genotype was either wild type, Bax
 
 
 
/
 
 
 
, Bak
 
 
 
/
 
 
 
,
Bax
 
 
 
/
 
 
 
 Bak
 
 
 
/
 
 
 
 double knockout (DKO), Bid
 
 
 
/
 
 
 
, or Bid
 
 
 
/
 
 
 
(provided by Dr. S. Korsmeyer, Harvard Medical School, Boston,
MA), were cultivated in IMDM (Life Technologies) supple-
mented with 20% FCS, 1
 
 
 
 NEAA (Sigma-Aldrich), and 100
U/ml penicillin/streptomycin at 37
 
 
 
C under 5% CO
 
2
 
 (5). MEF
from wild-type (WT), cathepsin B–deficient (24), cathepsin
L–deficient (25), cathepsin S–deficient (26), and cathepsin
D–deficient mice (provided by Dr. M. Boes, Harvard Medical
School, Boston, MA; reference 24) were immortalized with SV40
(27). Transfection with pcDNA3.1 vector only or p53-responsive
enhanced GFP plasmid (a gift from K. Wiman, Karolinska Cancer
Center, Stockholm, Sweden) was performed by electroporation
24 h before induction of cell death. The p53-responsive GFP
plasmid was generated by replacing the luciferase gene in
PG13PY Luc (a luciferase construct containing 13 repeats of the
p53-binding oligonucleotide 5
 
 
 
-CCTGCCCTGGGACTTGC-
CTGG-3
 
 
 
, a gift from Dr. B. Vogelstein, Johns Hopkins Univer-
sity, Baltimore, MD) with an EcoA7III–MluI fragment from
pEGFP-C1. DAP kinase cDNA and its mutants were a gift from
A. Kimchi (Weizmann Institute, Rehovot, Israel).
 
Cell Death Induction and Inhibition. 
 
Cells were cultured with
CPX (standard dose 350 
 
 
 
g/ml, Bayer), chloroquine (Sigma-
Aldrich), 1 
 
 
 
M staurosporine, 100 
 
 
 
M etoposide, 200 
 
 
 
M cis-
platin (Sigma-Aldrich), or a combination of anti-CD95 (clone
7C11, 100 ng/ml for 15 h; Immunotech) and 35 
 
 
 
M cyclohex-
imide. Serum withdrawal was performed for 24 h. Alternatively,
cells were incubated with NFX (standard dose 10 
 
 
 
g/ml; Sigma-
Aldrich) for 1 h and irradiated with a UV lamp (365 
 
 
 
 5 nm) at
12 J/cm
 
2
 
. 0.1 
 
 
 
M Bafilomycin A
 
1
 
 (Baf A
 
1
 
, Sigma-Aldrich), 100
 
 
 
M z-FA-fmk, 
 
N
 
-benzyloxycarbonyl-Phe-Ala-fluoromethylke-
tone; 100 
 
 
 
M z-VAD-fmk, 
 
N
 
-benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone (Bachem), 10 
 
 
 
M CA-074-Me (Peptides In-
ternational), 100 
 
 
 
M of pepstatin A (Sigma-Aldrich), 10 
 
 
 
M of
cyclic pifthrin-
 
 
 
 (Calbiochem), 10 mM GSH ethyl ester (Sigma-
Aldrich), or 100 
 
 
 
M MnTBAP (Calbiochem) were added 1 h
before induction of cell death. MEF (10
 
7
 
 in 150 
 
 
 
l RPMI 1640)
were electroporated (with a Bio-Rad gene pulser set at 250 V
and 960 
 
 
 
F) with 10 
 
 
 
g vector only (pcDNA3.1), WT DAP ki-
nase or its constitutively active or inactive mutants (DAP kinase
 
 
 
CaM or DAP kinase 
 
 
 
DD, respectively; reference 28), togetherT
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with 10 
 
 
 
g pDS-Red1-mito vector (CLONTECH Laboratories,
Inc.), for the identification of transfected (
 
 
 
50%) cells.
 
Lysosomal Stability Assessment. 
 
To determine the intracellu-
lar localization of NFX and CPX, cells cultured on coverslips
were loaded with 10 
 
 
 
g/ml of the antibiotics and visualized un-
der fluorescence microscopy. To label lysosomes, cells were in-
cubated with 0.5 
 
 
 
M of LysoTracker red (Molecular Probes)
for 15 min at 37
 
 
 
C and visualized by fluorescence microscopy
(10, 29) or with acridine orange (AO, 5 
 
 
 
M, 30 min, 37
 
 
 
C),
followed by determination of the red AO fluorescence by flow
cytometry (30).
 
Flow Cytometry. 
 
We used 40 nM 3, 3
 
 
 
 dihexyloxacarbocya-
nine iodide (DiOC
 
6
 
(3)) for 
 
  
 
m
 
 quantification, 1 
 
 
 
g/ml propid-
ium iodide (PI) for determination of cell viability, 10 
 
 
 
M hydro-
ethidine ( Molecular Probes) for the determination of superoxide
anion generation, and Annexin V conjugated with fluorescein
isothiocyanate kit (Bender Medsystems) for the assessment of
phosphatidylserine (PS) exposure (31). Quantification of DNA
 
content was performed on ethanol-fixed cells which were stained
with 4
 
 
 
,6-diamidino-2-phenylindole (DAPI; 2.5 
 
 
 
g/ml; Molec-
ular Probes) for 30 min at 37
 
 
 
C.
 
Light Microscopy and Immunofluorescence. 
 
Cells cultured on cov-
erslips were stained with 3 
 
 
 
M 5,5
 
 
 
,6,6
 
 
 
-tetrachloro-1,1
 
 
 
,3,3
 
 
 
-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1; Molecular
Probes) and 2 
 
 
 
M Hoechst 33342 (Sigma-Aldrich), followed by
fluorescence microscopic assessment. Alternatively, cells were
fixed with paraformaldehyde (4% wt/vol) and picric acid (0.19%
vol/vol) for immunofluorescence assays (32). Cells were stained
for the detection of cytochrome 
 
c
 
 (mAb 6H2.B4; BD Bio-
sciences), activated Bax (mAb 6A7; BD Biosciences), activated
Bak (mAb Ab-1 specific for the NH
 
2
 
 terminus, Oncogene Re-
search Products), cathepsin B (Calbiochem), and monoclonal
anti–cathepsin D (clone CTD-19; Sigma-Aldrich); all were de-
tected by a goat anti–mouse or goat anti–rabbit IgG conjugated
with Alexa
 
®
 
 Fluor (Molecular Probes; reference 33). Giemsa
stainings were performed with a kit from Sigma-Aldrich.
Figure 1. Specific lysosomal
destabilization by NFX* and
CPX. (A) Lysosomal localization
of NFX and CPX. HeLa cells
were incubated with 10  g/ml
NFX or CPX, and the CPX- or
NFX-mediated fluorescence was
determined in control cells or in
cells pretreated with 100 nM Baf
A1. The percentage of cells ex-
hibiting a clear cytoplasmic
punctate (lysosomal) or a nucle-
olar staining was determined. (B
and C) NFX*- and CPX-medi-
ated disruption of acidic vacu-
oles. Cells were stained with
LysoTracker red (B) or AO (C)
after treatment with UV, NFX
alone, NFX*, or CPX, followed
by fluorescence microscopy (B)
or cytofluorometric analysis of
the 630   11-nm fluorescence
(C). Numbers indicate the per-
centage of cells with decreased
AO red fluorescence. (D and E)
Translocation of cathepsins B
and D from lysosomes. Cells
treated for 8 h were fixed, per-
meabilized, and stained for the
immunofluorescence of cathep-
sin B (D) and D (E). Results are
representative of three to five in-
dependent determinations.T
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1326 Lysosome-triggered Mitochondrial Cell Death
Electron Microscopy.  Cells were fixed for 1 h at 4 C in 2.5%
glutaraldehyde in phosphate buffer (pH 7.4), washed, and fixed
again in 2% osmium tetroxide before embedding in Epon. Elec-
tron microscopy was performed with an transmission electron
microscope (model EM902; Carl Zeiss MicroImaging, Inc.), at
80 kV, on ultrathin sections (80 nm) stained with uranyl acetate
and lead citrate.
Immunoblot.  After the different treatments, cells were lysed
for 15 min in 50 mM Hepes, 150 mM NaCl, 5 mM EDTA, and
0.1% NP-40, supplemented with protease inhibitor cocktail (1
Figure 2. Caspase-indepen-
dent cell death induction by
NFX* and CPX. (A) PS expo-
sure resulting from lysosomal de-
stabilization. After the indicated
treatment, cells were stained for
PS exposure (with annexin
V–FITC) or plasma membrane
permeabilization (with PI) and
subjected to cytofluorometric
analysis. Numbers in each quad-
rant refer to the percentage of
cells. (B) Quantitation of data
obtained in A. (C) DNA hypo-
diploidy induced by NFX* and
CPX. After 24 h, the nuclear
DNA content was determined
with DAPI by cytofluorometric
analysis in fixed-permeabilized
cells. Numbers indicate the per-
centage of cells exhibiting a sub-
diploid (apoptotic) DNA content.
(D) Immunoblot determination
of caspase-3 maturation. Cell ex-
tracts obtained after the indicated
treatment and interval were sub-
jected to immunoblotting with
antibodies specific for cleaved
caspase-3 (17-kD fragment) and
glyceraldehyde-3-phosphate de-
hydrogenase (as a loading con-
trol). (E) Giemsa staining of
HeLa cells treated with NFX*,
CPX, or  CD95, in the absence
or presence of 100  M z-VAD-
fmk. (F) Chromatin structure of
living HeLa cells stably express-
ing a histone H2B-GFP fusion
protein after treatment with
NFX* or CPX. Representative
micrographs of the GFP fluores-
cence and phase-contrast pic-
tures are shown. (G) Ultrastruc-
ture of NFX*- or CPX-treated
cells exhibiting nuclear chroma-
tin condensation and vacuoliza-
tion, as compared with apopto-
sis induced by  CD95. (H)
Chromatin condensation in-
duced by NFX* or CPX, both
in the absence or presence of 100
 M z-VAD-fmk, as determined
in F. (I) Failure of z-VAD-fmk
(100  M) to inhibit PS exposure
in NFX*- and CPX-treated
cells. Data are shown as mean
values   SD of three indepen-
dent experiments.T
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mM DTT and 1 mM PMSF; Roche), and centrifuged at 13,000 g
for 10 min to remove cell debris. Total protein content was de-
termined with the Bio-Rad DC kit. 40  g of protein were
loaded on a 15% SDS-PAGE. Anti-cleaved caspase-3 antibody
(Cell Signaling Technology) was used to determine caspase-3
activation and anti–glyceraldehyde-3-phosphate dehydrogenase
(Chemicon) was used as a loading control.
Results and Discussion
NFX and CPX Induce Permeabilization of Lysosomal Mem-
branes.  Based on the intrinsic low-level fluorescence of
NFX and CPX (34), we determined their subcellular local-
ization. Both agents were found enriched in the nucleolus
as well as in cytoplasmic vesicles (Fig. 1 A). Inhibition of
the lysosomal vacuolar H  ATPase with Baf A1 abolished
the cytoplasmic (but not the nucleolar) accumulation of
NFX and CPX, indicating that the NFX/CPX-containing
vesicles are lysosomes (Fig. 1 A). Cells exposed to NFX or
to a low dose of UV light alone exhibited normal staining,
with two acidophilic dyes specifically labeling lysosomes:
namely a punctate lysosomal staining with LysoTracker red
(Fig. 1 B) and a marked red fluorescence with AO (Fig. 1
C). When NFX was combined with UV light (NFX*), an
immediate phototoxic effect was noted at the level of lyso-
somes, leading to the loss of the punctate LysoTracker red
staining pattern (Fig. 1 B) and a diminution of the red AO
fluorescence (Fig. 1 C). NFX*, but not NFX or UV light
alone, caused lysosomes to release cathepsins B and D into
Figure 3. MMP induced by
NFX* and CPX. (A) Dissipation
of the mitochondrial transmem-
brane potential (  m). After
NFX* (or UV and NFX alone)
or CPX treatment, cells were
stained simultaneously with
DiOC6(3), which incorporates
into cells driven by the   m,
and the vital marker propidium
iodide (PI). (B) Dose response of
the   m dissipation and viability
loss induced by NFX* and CPX,
determined as in A. (C) In situ
determination of   m loss, as
indicated by the spectral red–
green shift of JC-1–stained cells.
(D) In situ evidence for outer
mitochondrial membrane per-
meabilization. After an 8-h treat-
ment and fixation, cells were
stained for the immunodetec-
tion of cytochrome c (green fluo-
rescence) and counterstained
with Hoechst 33324. (E) Caspase
independence of mitochondrial
changes. Cells were pretreated
(60 min) with subtoxic doses of
z-VAD-fmk (100  M), exposed
overnight to NFX* or CPX, fol-
lowed by detection of   m re-
duction. (F) Cytochrome c re-
lease occurs after cathepsin B
translocation. Cells were treated
for 8 h with NFX* or CPX and
subjected to simultaneous immu-
nofluorescence staining for cyto-
chrome c (red) and cathepsin B
(green). Note that some cells (ar-
rows) have a diffuse cathepsin B
distribution, yet still retain cyto-
chrome c in a punctate pattern.T
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1328 Lysosome-triggered Mitochondrial Cell Death
the cytosol (Fig. 1, D and E). Similarly, CPX reduced
LysoTracker incorporation (Fig. 1 B), attenuated AO stain-
ing (Fig. 1 C), and led to the translocation of cathepsins B
and D (Fig. 1, D and E). In conclusion, NFX mediates the
UV-elicited (photodynamic) permeabilization of lysosomal
membranes, and CPX alone exerts similar effects.
NFX* and CPX Induce Caspase-independent Cell Death
with MMP.  The combination of NFX and UV light
(NFX*), as well as CPX alone, induced several hallmarks of
apoptosis, in particular the exposure of residues on the
plasma membrane surface (Fig. 2, A and B) and the loss of
nuclear DNA (Fig. 2 C). Although CPX caused proteolytic
maturation of caspase-3, NFX* failed to induce caspase
activation, as determined by immunoblots (Fig. 2 D). Im-
portantly, treatment with the pan-caspase inhibitor z-VAD-
fmk failed to prevent the induction of chromatin condensa-
tion by NFX* or CPX, as determined by Giemsa staining
(Fig. 2 E) as well as in unfixed cells engineered to stably ex-
press a histone H2B-GFP chimera, allowing for the con-
stant monitoring of chromatin structure (Fig. 2, F and H).
Figure 4. NFX* and CPX exert their mitochondriotoxic and cyto-
toxic effect via lysosomes. (A and B) Effect of the vacuolar ATPase inhib-
itor Baf A1 on   m loss and cell death. Cells were pretreated for 1 h with
Baf A1 and exposed overnight to NFX* or CPX, followed by staining
with DiOC6(3) (A) and PI (B). (C and D) Baf A1–mediated protection
against lysosomal and mitochondrial permeabilization. Cells treated as in
A and B were subjected to immunofluorescence detection of cytochrome
c (C) or cathepsin B (D). Representative cells showing that Baf A1 pre-
treatment maintains cytochrome c and cathepsin B in cytoplasmic or-
ganelles are shown.
Figure 5. Activation of Bax and Bak by NFX* and CPX through a
p53-independent mechanism. (A) Conformational change of Bax and
Bak. Cells were stained with monoclonal antibodies recognizing the ap-
optotic conformation of Bax (6A7) and Bak (Ab-1) 8 h after treatment
with NFX* or CPX. (B) Time course of lysosomal and mitochondrial
permeabilization induced by NFX* and CPX, as determined by staining
with LysoTracker Red and DiOC6(3) in unfixed cells. (C) Kinetics of
NFX*- and CPX-induced lysosomal cathepsin B release, Bax activation
(determined as in A), mitochondrial cytochrome c release, and caspase-3
activation, as determined by immunofluorescence of fixed and permeabi-
lized cells. Results are representative of three experiments. (D) Failure of
NFX* and CPX to activate p53-dependent transcription. Cells were
transfected with a p53-inducible GFP reporter construct, and the per-
centage of cells expressing GFP was determined by FACS® analysis. DNA
damage by etoposide served as positive control. (E) Failure of pifithrin- 
to inhibit NFX*- and CPX-induced cell death. Cells were pretreated for
60 min with the p53 inhibitor pifithrin- , and the frequency of 
(DiOC6(3)low) and death (PIhigh) was determined by cytofluorometry.
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1329 Boya et al.
This chromatin condensation was less pronounced as that
induced by CD95 cross-linking (which, however, was fully
inhibited by z-VAD-fmk) (Fig. 2, E, F, and H), and was of
a more peripheral type, as determined by electron micros-
copy (Fig. 2 G). z-VAD-fmk failed to prevent PS exposure
induced by NFX* or CPX (Fig. 2 I). NFX* and CPX in-
duced signs of MMP such as the dissipation of   m, mea-
sured as a reduction of the DiOC6(3) incorporation (Fig. 3,
A and B) or a spectral red–green shift in the fluorescence of
JC-1 (Fig. 3 C), and the mitochondrial release of cyto-
chrome c (Fig. 3 D). Again, z-VAD-fmk failed to affect the
signs of MMP induced by NFX* or CPX (Fig. 3 E). The
population of cells having released cytochrome c from
mitochondria constituted a subensemble of NFX*- or
CPX-treated cells with diffuse cathepsin B staining (Fig. 3
F), indicating that MMP occurs after lysosomal membrane
permeabilization (LMP). Baf A1 inhibited all hallmarks of
cell death induced by NFX* or CPX: loss of the   m (Fig.
4 A), loss of viability (Fig. 4 B), mitochondrial release of
cytochrome c (Fig. 4 C), and lysosomal release of cathepsin
B (Fig. 4 D). In conclusion, NFX* and CPX induce MMP
and z-VAD-fmk–resistant cell death via a pathway that
strictly depends on their Baf A1–inhibitable accumulation
in lysosomes.
Lysosomal Damage Triggers MMP and Cell Death via Bax
and Bak.  Both NFX* and CPX induced a conforma-
tional change of Bax and Bak (detectable with monoclonal
antibodies specific for the NH2 terminus of these mole-
cules), which are exposed only in the “apoptotic confor-
mation” (35, 36). Both NFX* and CPX treatment resulted
in a punctate cytoplasmic staining of apoptotic Bax and
Bak (Fig. 5 A), which were found to colocalize with the
mitochondrial marker Hsp60 (not depicted). The activa-
tion of Bax and Bak occurs after LMP (as assessed by mea-
suring the LysoTracker red incorporation and cathepsin B
release), but before the mitochondrial release of cyto-
chrome c and before caspase-3–activation (Fig. 5, B and
C). These alterations were not due to transcriptional acti-
vation of p53 because NFX* and CPX (in contrast to the
positive control etoposide) failed to induce a p53-inducible
GFP reporter gene (Fig. 5 D). Moreover, NFX*- and
CPX-induced MMP and cell death were not inhibited by
pifithrin- , a chemical inhibitor of p53-mediated transacti-
vation (Fig. 5 E) or cycloheximide, a general inhibitor of
Figure 6. Requirement of Bax and/or Bak for
NFX*- or CPX-induced cell death. (A) SV40-trans-
formed WT MEF or Bax /  Bak /  DKO cells were
exposed to NFX* and CPX for the indicated period,
followed by determination of the frequency of
DiOC6(3)low and annexin V–positive cells. (B) MEF
lacking Bax, Bak, Bax and Bak (DKO), or Bid were
exposed to either NFX* or CPX and the indicated pa-
rameters were measured. (C) NFX*- and CPX-
induced cathepsin B release in control and Bax / 
Bak /  DKO cells, as determined by immunostaining.
The percentage of cells exhibiting diffuse cathepsin B
staining as well as those with diffuse cytochrome c
staining has been quantified. (D) Failure of chemical
cathepsin inhibition to prevent NFX*- or CPX-
induced cell death. HeLa cells were pretreated with the
indicated cathepsin inhibitors, followed by determina-
tion of the frequency of DiOC6(3)low and PIhigh cells.
(E) Cathepsins are dispensable for NFX*- or CPX-
induced cell death. MEF with the indicated genotypes
were treated with NFX* or CPX, and apoptotic pa-
rameters were measured as in D. Results are means  
SD of three independent determinations.T
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protein synthesis (not depicted). To directly address the
contribution of Bax and Bak to cell death induced by lyso-
motropic agents, we took advantage of SV40–immortal-
ized MEF lacking Bax, Bak, Bid, or both Bax and Bak.
Bax / Bak /  DKO were found to be profoundly resis-
tant to the induction of MMP and PS exposure by NFX*
or CPX (Fig. 6 A). Only the DKO of Bax and Bak led to
cytoprotection against NFX* (Fig. 6 B). In contrast, the
absence of either Bax or Bak (but not Bid) was sufficient to
prevent cell death induction by CPX (Fig. 6 B). WT and
Bax / Bak /  cells exposed to CPX or NFX* underwent
a similar degree of lysosomal disruption, as measured with
cathepsin B immunostaining (Fig. 6 C). However, Bax / 
Bak /  cells manifested much less diffuse cytochrome c
staining induced by CPX or NFX*, as compared with
controls (Fig. 6 C). The knockout of the genes coding for
cathepsin B, D, L, or S and several cathepsin inhibitors
failed to prevent CPX- or NFX-induced MMP and cell
death (Fig. 6, D and E). Altogether, these data demonstrate
that Bax and/or Bak, but not cathepsins, control cell death
induced by lysosomotropic agents.
Mitochondrial Bcl-2 and vMIA Selectively Inhibit CPX-medi-
ated MMP and Cell Death.  HeLa cells stably transfected
with Bcl-2 or vMIA, a cytomegalovirus-encoded protein
that interacts with the mitochondrial adenine nucleotide
translocase (20), exhibited a relative resistance to the induc-
tion of   m loss and cell death by CPX but not by NFX*
(Fig. 7 A). Bcl-2 specifically targeted to the mitochondrial
outer membrane (Bcl-2 acta) was as efficient as WT Bcl-2
in inhibiting CPX-induced MMP and cell killing (Fig. 7
B). In contrast, ER-targeted Bcl-2 (Bcl-2 cathepsin B5;
references 22, 23) failed to antagonize CPX (Fig. 7 B).
Bcl-2 and vMIA failed to antagonize the dissipation of
LysoTracker red staining by CPX (Fig. 7 C). Thus, Bcl-2
and vMIA inhibit CPX but not NFX*-induced cell death
at the mitochondrial level.
Involvement of Reactive Oxygen Species (ROS) as Mediators
of MMP in NFX*-induced Cell Death.  The NFX*-
induced   m loss was preceded by an increase in ROS
production (as quantified by the ROS-mediated conver-
sion of hydroethidine into the fluorescent product ethid-
ium), whereas CPX-induced   m loss occurred before
ROS production increased (Fig. 8 A). Furthermore, the
antioxidants glutathione ethyl ester and MnTBAP pre-
vented NFX*-induced MMP, ROS generation, PS expo-
sure, and cell death, yet had no effect on CPX-induced cell
death (Fig. 8, B and C). MnTBAP also inhibited the NFX-
induced apoptotic conformation of Bax, yet had no signifi-
Figure 7. Mitochondrial membrane stabilization by
Bcl-2 or vMIA prevent CPX-induced cell death. (A)
HeLa cells stably transfected with vector only (Neo), or
cDNAs coding for human Bcl-2 or cytomegalovirus-
derived vMIA were treated with NFX* or CPX, and
the frequency of DiOC6(3)low or PIhigh cells was as-
sessed. Note that Bcl-2– and vMIA-expressing cells are
more susceptible to cell death induction by NFX*, yet
relatively resistant to CPX. (B) Mitochondrial, not
ER-localized, Bcl-2 prevents CPX-induced cell death.
Rat1 cells stably transfected with vector only (Neo),
WT Bcl-2, mitochondrion-targeted Bcl-2 (Bcl-2 acta),
and ER-targeted Bcl-2 (Bcl-2 cathepsin B5), were sub-
jected to the indicated treatment, and the loss of mito-
chondrial and plasma membrane integrity was assessed
with DiOC6(3) and PI, respectively. (C) Failure of Bcl-2
or vMIA to confer lysosomal stabilization. HeLa cells
expressing Neo, Bcl-2, or vMIA were treated with
NFX* or CPX, fixed, and immunostained for cathep-
sin B. Note that all cells exhibit a diffuse cathepsin B
staining, although Bcl-2 and vMIA do inhibit CPX-
induced MMP (A) and cell death (B) as an internal
control of their efficacy.T
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cant effect on CPX-induced Bax activation (Fig. 8 D). The
antioxidant partially ( 60%) inhibited the NFX* (but not
the CPX)-induced cathepsin B relocalization (Fig. 8 E).
Thus, NFX* induces cell death through a photodynamic
effect involving ROS upstream of MMP, whereas ROS
are not involved in CPX-induced MMP.
MMP Is a General Requirement for Lysosome-initiated Cell
Death.  As shown in Fig. 9 A, the cytotoxic effect of
chloroquine, yet another lysosomotropic drug, is abolished
by either Baf A1 or by the DKO of Bax and Bak. The ab-
sence of Bax and Bak also inhibited the   m loss (Fig. 9
A), the release of cytochrome c, and chromatin condensa-
tion induced by chloroquine, yet had no effect on the
translocation of cathepsin B (Fig. 9 B). The constitutively
active DAP kinase (DAP kinase  CaM) has been shown to
stimulate a lysosomal/autophagic cell death pathway, when
overexpressed in HeLa cells (28). DAP kinase  CaM (but
not WT DAP kinase or the inactive DAP kinase  DD mu-
tant) induces a   m loss and kills WT MEF, yet has no
major effect on Bax /  Bak /  MEF. These findings con-
firm that Bax/Bak-dependent MMP is involved in lyso-
some-triggered cell death.
Concluding Remarks.  We report here the unexpected
finding that MMP occurs downstream of LMP, as a down-
stream rate-limiting step of cellular demise, based on sev-
eral signs of evidence. First, LMP is detectable within a
few hours after NFX* or CPX treatment, whereas MMP
appears later (Figs. 1 and 3 and Fig. 5, B and C). Second,
cells with signs of MMP (e.g., cytochrome c release) are a
sub-ensemble of cells with signs of LMP (e.g., cathepsin B
release), not vice versa (Fig. 3). Third, inhibition of LMP
with Baf A1 suppresses MMP (Fig. 4), whereas prevention
of MMP by the Bax/Bak DKO, Bcl-2, or vMIA does not
block LMP (Figs. 6 C, 7 C, and 9 B). Fourth, when MMP
is prevented (by deletion of Bax and/or Bak or overex-
pression of Bcl-2 or vMIA), LMP fails to cause late mani-
festations of cell death such as PS exposure, (partial) chro-
matin condensation, and loss of viability (Figs. 6 and 7).
Importantly, the evidence placing LMP upstream of MMP
has been obtained with three different clinically relevant
drugs (NFX*, CPX, and chloroquine), as well as with
DAP-kinase, a signal-transducing molecule known to be
involved in physiological cell death induction by  -inter-
feron and TNF-  (Fig. 9; reference 28). Thus, the impor-
tance of MMP for LMP-induced cell death appears to be a
general phenomenon.
Although these data imply a clear hierarchical relation-
ship between LMP and MMP with regards to cell death in-
duction (Fig. 10), the molecular link between LMP and
MMP remains elusive. The lysosomal cathepsins B, D, L,
and S do not constitute such a link, as shown by the
knockout of each of these cathepsins (Fig. 6 E), as well as
by pharmacological studies involving cathepsin inhibitors
(Fig. 6 D). Moreover, although the proapoptotic Bcl-2–
like protein Bid could constitute a link between LMP and
MMP (37, 38), Bid clearly does not contribute to MMP
induced by CPX or NFX*, as demonstrated by experi-
ments involving Bid /  cells (Fig. 6 B). p53-mediated ef-
fects, which also have been postulated to participate in
LMP-induced apoptosis (39, 40), clearly do not participate
Figure 8. Differential involvement of
ROS in CPX- and NFX-induced cell
death. (A) Relationship between ROS pro-
duction and   m loss triggered by NFX*
and CPX. HeLa cells were exposed to
NFX* or CPX for the indicated interval,
and stained simultaneously with the   m-
sensitive dye DiOC6(3) and the ROS-sensi-
tive probe hydroethidine (HE), whose oxi-
dation by superoxide anions yields the red
fluorescent product ethidium (Eth). Note
that NFX*treatment causes ROS produc-
tion before the   m drops, whereas after
CPX treatment, ROS production is only
observed in a subpopulation of DiOC6(3)low
cells. (B–E) Effects of antioxidants on CPX-
and NFX-induced cell death. HeLa cells
were pretreated (60 min) with the cell-per-
meable GSH ethyl ester (10 mM) or the
superoxide dismutase analogue MnTBAP
(100  M), followed by overnight treatment
with NFX* or CPX and determination of
the frequency of  , ROS-overpro-
ducing (B), PS-exposing, dead (C) cells, and
cells exhibiting Bax in the apoptotic confor-
mation (D, determined with the conforma-
tion-specific 6A7 mAB as in Fig. 5 A) and
diffuse cathepsin B staining (E, determined
as in Fig. 1 D).
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in CPX- or NFX-induced MMP, which is independent of
the transcription of p53 target genes (Fig. 5, D and E). It
has been suggested that cathepsin B would directly activate
caspase-3 (41) and/or trigger apoptotic chromatin conden-
sation and nuclear DNA loss (15). However, the presence
of cathepsin B in the cytosol and in the nucleus clearly is
not sufficient to induce cell death, as shown by the fact that
Bax / Bak /  cells can release cathepsin from lysosomes,
yet fail to translocate cytochrome c and continue to mani-
fest a normal chromatin structure (Figs. 6 C and 9 B).
Clear differences appear in the mechanisms through
which NFX* and CPX induce MMP and cell death, the
first one involving ROS (as to be expected for a photosen-
sitizer) and the second acting independently from ROS
(Fig. 8). Moreover, the NFX-induced MMP was more
difficult to be inhibited than CPX-induced MMP. Only
the knockout of both Bax and Bak conferred resistance to
NFX* (Fig. 6, A and B). The knockout of either Bax or
Bak alone, or the overexpression of vMIA, natural Bcl-2,
or mitochondrion-targeted Bcl-2 did not attenuate the
NFX-triggered MMP and death, whereas all these manip-
ulations did prevent CPX-mediated MMP (Figs. 6 and 7).
Although NFX failed to cause the activation of caspase-3,
CPX triggered the proteolytic maturation of caspase-3
(Fig. 2 D). However, caspase inhibition did not block cell
death in CPX- or NFX-treated cells (Fig. 2, F and G),
which is as in line with the notion that caspase-indepen-
dent death effectors seal the cell’s fate in response to lyso-
somotropic agents. The ROS-inducing property of NFX*
may explain why it acts as a stronger MMP inducer, yet as
a weaker caspase elicitor than CPX. Indeed, it is known
that primary thiol oxidation of mitochondrial proteins
(which may result from an oxidative shift in the cellular re-
dox potential) can induce a Bcl-2–refractory MMP (42–
44) and that Bcl-2 can even sensitize to (ROS-mediated)
photodynamic therapy (45). Moreover, oxidation of criti-
cal thiols within the catalytic center of caspases annihilates
their latent proteolytic potential and, thus, precludes their
(auto)activation (46).
In conclusion, the data reported herein reveal that MMP
may be indispensable for cell death initiated at the lysoso-
mal level, thus reenforcing the concept that MMP consti-
tutes a central event in the death-inducing signaling cas-
cade. Based on these results, studies are underway to
explore the possibility that prevention of MMP might di-
minish pathogenic cell loss triggered by primary lysosomal
lesions in pathologies as diverse as Gaucher disease, Sand-
hoff disease, Farber disease, Niemann Pick disease, neuronal
ceroid lipofuscinosis, and age-related macular degeneration.
Figure 9. Effect of the Bax/Bak DKO on apoptosis
induced by two different lysomal stimuli. (A) Chloro-
quine-induced   m loss and cell death is inhibited by
Baf A1 as well as by ablation of Bax and Bak. WT MEF
or DKO MEF were exposed to 30  g/ml chloroquine
(24 h), followed by determination of DiOC6(3)/PI
staining and flow cytometric analysis. (B) Chloro-
quine-induced cathepsin B translocation, cytochrome c
release, and chromatin condensation are inhibited in
DKO cells. Cells, treated as in A, were subjected to
immunofluorescence analysis (anti–cathepsin B, anti–
cytochrome c, and Hoechst 33324), and the cells ex-
hibiting the indicated phenotype were determined. (C)
DAP kinase-induced cell death and   m loss in WT
and DKO MEF. Cells were transfected with the con-
stitutively active DAP kinase construct  CaM or con-
trols. After 72 h, the cells were stained with DiOC6(3)
and DAPI, and the percentage of 
(DiOC6(3)low) or dead (DAPI ) cells was measured by
cytofluorometry.
∆Ψm
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Figure 10. Hypothetical mechanisms through which CPX and NFX*
kill cells. CPX causes death through lysosomal membrane permeabiliza-
tion (LMP), upstream of MMP, caspase-3 activation, and activation of
caspase-independent death effectors including ROS. NFX* causes death
through ROS-mediated phototoxic effects, upstream of LMP, and MMP.
Perhaps as a result of the primary effect on cellular redox potentials,
MMP occurs in a Bcl-2–independent fashion and does not result in
caspase-3 activation.T
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